Inclusion complex of erlotinib with sulfobutyl ether-β-cyclodextrin: Preparation, characterization, in silico, in vitro and in vivo evaluation

Carbohydrate Polymers

Volumn 134, Issue , 2015, Pages 547-556

  Devasari, Naresh ^a   Dora, Chander Parkash ^a   Singh, Charan ^a   Paidi, Sharan Reddy ^a   Kumar, Vivek ^a   Sobhia, Masilamani Elizabeth ^a   Suresh, Sarasija ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

Cyclodextrin; Erlotinib; Pancreatic cancer; Solubility enhancement; Sulfobutyl ether cyclodextrin; Tyrosine kinase inhibitor

Indexed keywords

AMINO ACIDS; BIOCHEMISTRY; CYCLODEXTRINS; DIFFERENTIAL SCANNING CALORIMETRY; DISSOLUTION; ETHERS; FOURIER TRANSFORMS; INFRARED SPECTROSCOPY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; SOLUBILITY; X RAY DIFFRACTION ANALYSIS;

ERLOTINIB; FOURIER TRANSFORMATIONS; OPTIMAL EXPERIMENTAL DESIGNS; PANCREATIC CANCERS; PHASE-SOLUBILITY STUDIES; PROTON NUCLEAR MAGNETIC RESONANCE; SOLUBILITY ENHANCEMENT; TYROSINE KINASE INHIBITOR;

NUCLEAR MAGNETIC RESONANCE;

BETA CYCLODEXTRIN DERIVATIVE; DRUG CARRIER; ERLOTINIB; SBE4-BETA-CYCLODEXTRIN;

ANIMAL; BIOAVAILABILITY; CHEMICAL STRUCTURE; CHEMISTRY; CONFORMATION; DRUG RELEASE; MEDICINAL CHEMISTRY; ORAL DRUG ADMINISTRATION; RAT; SOLUBILITY; SPRAGUE DAWLEY RAT;

ADMINISTRATION, ORAL; ANIMALS; BETA-CYCLODEXTRINS; BIOLOGICAL AVAILABILITY; CARBOHYDRATE CONFORMATION; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; DRUG LIBERATION; ERLOTINIB HYDROCHLORIDE; MODELS, MOLECULAR; RATS; RATS, SPRAGUE-DAWLEY; SOLUBILITY;

EID: 84939833101     PISSN: 01448617     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.carbpol.2015.08.012     Document Type: Article

References (41)

1. W. Chen, L.J. Yang, S.X. Ma, X.D. Yang, B.M. Fan, and J. Lin Crassicauline A/β-cyclodextrin host-guest system: Preparation, characterization, inclusion mode, solubilization and stability Carbohydrate Polymers 84 4 2011 1321 1328
2. I. Correia, N. Bezzenine, N. Ronzani, N. Platzer, J.C. Beloeil, and B.T. Doan Study of inclusion complexes of acridine with β-and (2,6-di-O-methyl)-β-cyclodextrin by use of solubility diagrams and NMR spectroscopy Journal of Physical Organic Chemistry 15 9 2002 647 659
3. E.M. Del Valle Cyclodextrins and their uses: A review Process Biochemistry 39 9 2004 1033 1046
4. C.P. Dora, S.K. Singh, S. Kumar, A.K. Datusalia, and A. Deep Development and characterization of nanoparticles of glibenclamide by solvent displacement method Acta Poloniae Pharmaceutica 67 2010 283 290
5. J. Dowell, J.D. Minna, and P. Kirkpatrick Erlotinib hydrochloride Nature Reviews Drug Discovery 4 1 2005 13 14
6. M. Frisch, G. Trucks, H.E.A. Schlegel, G. Scuseria, M. Robb, J. Cheeseman, and et al. Gaussian 03, revision C. 02 2008
7. T. Higuchi, and K.A. Connors Phase-solubility techniques Advances in Analytical Chemistry and Instrumentation 4 2 1965 117 212
8. P. Jadhav, B. Petkar, Y. Pore, A. Kulkarni, and K. Burade Physicochemical and molecular modeling studies of cefixime-l-arginine-cyclodextrin ternary inclusion compounds Carbohydrate Polymers 98 2 2013 1317 1325
9. A.C. Jain, and M.C. Adeyeye Hygroscopicity, phase solubility and dissolution of various substituted sulfobutylether β-cyclodextrins (SBE) and danazol-SBE inclusion complexes International Journal of Pharmaceutics 212 2 2001 177 186
10. A.S. Jain, A.A. Date, R.R. Pissurlenkar, E.C. Coutinho, and M.S. Nagarsenker Sulfobutyl ether7 β-cyclodextrin (SBE7 β-CD) carbamazepine complex: Preparation, characterization, molecular modeling, and evaluation of in vivo anti-epileptic Activity AAPS PharmSciTech 12 4 2011 1163 1175
11. P. Job Formation and stability of inorganic complexes in solution Annali Di Chimica 9 1928 113 203
12. G. Jones, P. Willett, R.C. Glen, A.R. Leach, and R. Taylor Development and validation of a genetic algorithm for flexible docking Journal of Molecular Biology 267 3 1997 727 748
13. C. Jullian, J. Morales-Montecinos, G. Zapata-Torres, B. Aguilera, J. Rodriguez, V. Arán, and et al. Characterization, phase-solubility, and molecular modeling of inclusion complex of 5-nitroindazole derivative with cyclodextrins Bioorganic & Medicinal Chemistry 16 9 2008 5078 5084
14. P.R. Jyothi, K.S.B. Adibhatla, and C.N. Venkaiah Novel polymorphs of erlotinib hydrochloride and method of preparation WO2008102369 A1 2008
15. V.T. Karathanos, I. Mourtzinos, K. Yannakopoulou, and N.K. Andrikopoulos Study of the solubility, antioxidant activity and structure of inclusion complex of vanillin with β-cyclodextrin Food Chemistry 101 2 2007 652 658
16. S. Kumar, C. Parkash, P. Kumar, and S. Singh Application of some novel techniques for solubility enhancement of mefenamic acid, a poorly water soluble drug International Journal of Pharmaceutical Sciences and Drug Research 1 3 2009 164 171
17. S. Kwon, W. Lee, H.J. Shin, S.I. Yoon, Y.T. Kim, Y.J. Kim, and et al. Characterization of cyclodextrin complexes of camostat mesylate by ESI mass spectrometry and NMR spectroscopy Journal of Molecular Structure 938 1 2009 192 197
18. S. Latha, S. Ananda Thangadurai, M. Jambulingam, K. Sereya, D. Kamalakannan, and M. Anilkumar Development and validation of RP-HPLC method for the estimation of erlotinib in pharmaceutical formulation Arabian Journal of Chemistry 2015 (in press)
19. G. Liversidge, and S. Jenkins Nanoparticulate erlotinib formulations EP 1871345 B1 2012
20. T. Loftsson, D. Hreinsdóttir, and M. Masson Evaluation of cyclodextrin solubilization of drugs International Journal of Pharmaceutics 302 1 2005 18 28
21. T. Loftsson, P. Jarho, M. Masson, and T. Järvinen Cyclodextrins in drug delivery Expert Opinion on Drug Delivery 2 2 2005 335 351
22. M.A. Lyra, J.L. Soares-Sobrinho, R.C. Figueiredo, J.M. Sandes, Á.A. Lima, R.P. Tenório, and et al. Study of benznidazole-cyclodextrin inclusion complexes, cytotoxicity and trypanocidal activity Journal of Inclusion Phenomena and Macrocyclic Chemistry 73 1-4 2012 397 404
23. D. Marion Reprint of "Application of phase sensitive two-dimensional correlated spectroscopy (COSY) for measurements of 1H-1H spin-spin coupling constants in proteins" Biochemical and Biophysical Research Communications 425 3 2012 519 526
24. G. Marslin, C.J. Sheeba, V. Kalaichelvan, R. Manavalan, P. Neelakanta Reddy, and G. Franklin Poly(d,l-lactic-co-glycolic acid) nanoencapsulation reduces erlotinib-induced subacute toxicity in rat Journal of Biomedical Nanotechnology 5 5 2009 464 471
25. W. Misiuk, and M. Zalewska Investigation of inclusion complex of trazodone hydrochloride with hydroxypropyl-β-cyclodextrin Carbohydrate Polymers 77 3 2009 482 488
26. R.B. Parthasaradhi, R.K. Rathnakar, R.R. Raji, R.D. Muralidhara, and R.T. Srinivasa Erlotinib hydrochloride polymorph form A substantially free of polymorph form B EP 221873 A1 2010
27. M.N. Reddy, T. Rehana, S. Ramakrishna, K. Chowdary, and P.V. Diwan β-Cyclodextrin complexes of celecoxib: Molecular-modeling, characterization, and dissolution studies AAPS PharmSci 6 1 2004 68 76
28. A. Ribeiro, A. Figueiras, D. Santos, and F. Veiga Preparation and solid-state characterization of inclusion complexes formed between miconazole and methyl-β-cyclodextrin AAPS PharmSciTech 9 4 2008 1102 1109
29. L. Ribeiro, T. Loftsson, D. Ferreira, and F. Veiga Investigation and physicochemical characterization of vinpocetine-sulfobutyl ether beta-cyclodextrin binary and ternary complexes Chemical & Pharmaceutical Bulletin (Tokyo) 51 8 2003 914 922
30. M. Serafini, P. Menezes, L. Costa, C. Lima, L. Quintans Jr., J. Cardoso, and et al. Interaction of p-cymene with β-cyclodextrin Journal of Thermal Analysis and Calorimetry 109 2 2012 951 955
31. J. Szejtli Medicinal applications of cyclodextrins Medicinal Research Reviews 14 3 1994 353 386
32. C. Tang, Y.X. Guan, S.J. Yao, and Z.Q. Zhu Solubility of dexamethasone in supercritical carbon dioxide with and without a cosolvent Journal of Chemical & Engineering Data 59 11 2014 3359 3364
33. G. Trapani, A. Latrofa, M. Franco, M.R. Pantaleo, E. Sanna, F. Massa, and et al. Complexation of Zolpidem with 2-hydroxypropyl-β-, methyl-β-, and 2-hydroxypropyl-γ-cyclodextrin: Effect on aqueous solubility, dissolution rate, and ataxic activity in rat Journal of Pharmaceutical Sciences 89 11 2000 1443 1451
34. V. Venuti, C. Cannavà, M.C. Cristiano, M. Fresta, D. Majolino, D. Paolino, and et al. A characterization study of resveratrol/sulfobutyl ether-β-cyclodextrin inclusion complex and in vitro anticancer activity Colloids and Surfaces B: Biointerfaces 115 2014 22 28
35. S. Vrignaud, J. Hureaux, S. Wack, J.-P. Benoit, and P. Saulnier Design, optimization and in vitro evaluation of reverse micelle-loaded lipid nanocarriers containing erlotinib hydrochloride International Journal of Pharmaceutics 436 1 2012 194 200
36. K. Waleczek, H. Marques, B. Hempel, and P. Schmidt Phase solubility studies of pure (-)-α-bisabolol and camomile essential oil with β-cyclodextrin European Journal of Pharmaceutics and Biopharmaceutics 55 2 2003 247 251
37. D.-W. Wang, C.-B. Ouyang, Q. Liu, H.-L. Yuan, and X.-H. Liu Inclusion of quinestrol and 2,6-di-O-methyl-β-cyclodextrin: Preparation, characterization, and inclusion mode Carbohydrate Polymers 93 2 2013 753 760
38. R.J. Westheim Hydrates of erlotinib hydrochloride EP2099772 A2 2013
39. H. Wu, H. Liang, Q. Yuan, T. Wang, and X. Yan Preparation and stability investigation of the inclusion complex of sulforaphane with hydroxypropyl-β-cyclodextrin Carbohydrate Polymers 82 3 2010 613 617
40. V.R. Yadav, S. Suresh, K. Devi, and S. Yadav Effect of cyclodextrin complexation of curcumin on its solubility and antiangiogenic and anti-inflammatory activity in rat colitis model AAPS PharmSciTech 10 3 2009 752 762
41. B. Yang, J. Lin, Y. Chen, and Y. Liu Artemether/hydroxypropyl-β-cyclodextrin host-guest system: Characterization, phase-solubility and inclusion mode Bioorganic & Medicinal Chemistry 17 17 2009 6311 6317